Scopus: 5 citations, Google Scholar: citations,
Ibrutinib repurposing : from B-cell malignancies to solid tumors
Massó Vallés, Daniel (Vall d'Hebron. Institut d'Oncologia)
Jauset, Toni (Vall d'Hebron. Institut d'Oncologia)
Soucek, Laura (Vall d'Hebron. Institut d'Oncologia)
Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular

Date: 2016
Abstract: Ibrutinib (Imbruvica®, also known as PCI-32765) is a first-in-class, irreversible small-molecule inhibitorof Bruton's Tyrosine Kinase (BTK) that binds covalently to cysteine C481 within the ATP-binding pocket. Since BTK is a Tec family non-receptor tyrosine kinase that is specifically required for B-cell antigen receptor (BCR) signaling, ibrutinib was initially developed for the treatment of B-cell malignancies. Currently, it is approved for first-line treatment of chronic lymphocytic leukemia, and for the treatment of mantle-cell lymphoma and Waldenström's macroglobulinemia patients that have received at least one previous therapy.
Note: Número d'acord de subvenció ISCIII/CP10-00656
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès.
Document: article ; recerca ; publishedVersion
Subject: Ibrutinib ; Drug repurposing ; Solid tumors ; Inflammation ; BTK
Published in: Oncoscience, Vol. 3, Num. 5-6 (may 2016) , p. 147-148, ISSN 2331-4737

PMID: 27489860
DOI: 10.18632/oncoscience.310


2 p, 193.7 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles

 Record created 2018-02-07, last modified 2019-03-07



   Favorit i Compartir